NCT03227328: CHemo-ENDOcrine Therapy in Advanced Breast Cancer

NCT03227328
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 3
Drug Category: Endocrine (Hormone) Therapy, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with active central nervous system metastases
https://ClinicalTrials.gov/show/NCT03227328

Comments are closed.

Up ↑